Method For The Identification Of Sepsis
First Claim
1. A method for the in vitro differentiation between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions, thereby characterized, that it includes the following steps:
- a) isolation of sample RNA from a biological sample;
b) marking the sample RNA and/or at least one DNA, which has a gene activity that is specific for distinguishing between SIRS and sepsis and/or is a specific gene or gene fragment, with a detectable marker;
c) bringing the sample RNA in contract with the DNA in hybridization conditions;
d) bringing control RNA in contact with at least one DNA, under hybridization condition, said DNA representing a gene or gene fragment that is specific for distinguishing between SIRS and sepsis;
e) quantitatively measuring the marking signals of the hybridized sample A and control RNA; and
f) comparing the quantitative data of the marking signals in order to make a determination as to whether genes or gene fragments that are specific for distinguishing between SIRS and sepsis are expressed more prominently or less prominently in the sample than in the control RNA.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to a method for the in vitro discrimination between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions. The method comprises the following steps: a) sample RNA is isolated from a biological sample; b) the sample RNA and/or at least one DNA which represents a gene activity that is specific for distinguishing between SIRS and sepsis and/or a specific gene or gene fragment, is marked with a detectable marker; c) the sample RNA is brought in contact with the DNA in hybridization conditions; d) control RNA is brought in contact with at least one DNA in hybridization conditions, the DNA representing a gene or gene fragment that is specific for distinguishing between SIRS and sepsis; e) the marking signals of the hybridized sample RNA and control RNA are quantitatively recorded; and f) the quantitative data of the marking signals is compared in order to make a statement as to whether genes or gene fragments that are specific for distinguishing between SIRS and sepsis are expressed more prominently or less prominently in the sample than in the control RNA.
36 Citations
32 Claims
-
1. A method for the in vitro differentiation between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions, thereby characterized, that it includes the following steps:
-
a) isolation of sample RNA from a biological sample; b) marking the sample RNA and/or at least one DNA, which has a gene activity that is specific for distinguishing between SIRS and sepsis and/or is a specific gene or gene fragment, with a detectable marker; c) bringing the sample RNA in contract with the DNA in hybridization conditions; d) bringing control RNA in contact with at least one DNA, under hybridization condition, said DNA representing a gene or gene fragment that is specific for distinguishing between SIRS and sepsis; e) quantitatively measuring the marking signals of the hybridized sample A and control RNA; and f) comparing the quantitative data of the marking signals in order to make a determination as to whether genes or gene fragments that are specific for distinguishing between SIRS and sepsis are expressed more prominently or less prominently in the sample than in the control RNA. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30)
-
-
26. Use of recombinant or synthetic produced nucleic acid sequences having specificity for distinguishing between SIRS and sepsis, or partial sequences individually or in subsets, as calibrators in sepsis-assays and/or for evaluation of the effectivity or toxicity in a screening for active substances and/or for production of therapeutics and of substances and substance mixtures, which can be used as therapeutics, for prevention and treatment between SIRS and sepsis.
-
31. Use of gene activity data for the production of software for diagnostic purposes and/or patient data management systems.
-
32. Use of gene activity data for provision of experimental systems for modeling of cellular signal transmitter pathways.
Specification